ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Advocacy
  • Artificial intelligence (AI)
  • Bladder cancer
  • Brain cancer
  • Breast cancer
  • Colorectal
  • ComboMATCH
  • COVID-19
  • Esophagus cancer
  • Head and neck cancer
  • Health equity
  • Imaging
  • Immunotherapy
  • In memory
  • Kidney cancer
  • Leukemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Mammography
  • Melanoma
  • Myelodysplastic syndrome
  • Myeloma
  • NCI-MATCH
  • Older adults
  • Pancreatic cancer
  • Pancreatic cysts
  • Patient education
  • Patient navigation
  • Patient-reported outcomes
  • Personalized treatment
  • Policy
  • Precision medicine
  • Prevention
  • Prostate cancer
  • Real-world data
  • Real-world evidence
  • Research results
  • Sarcoma
  • Screening for cancer
  • Side effects
  • Survivorship
  • Targeted therapy
  • Upper tract urothelial cancer
  • Young adults
March 23, 2023
March 23, 2023
Categories
  • New Trials

The ComboMATCH precision medicine initiative is getting set to evaluate several new anti-cancer drug combinations

Hospitals and cancer centers nationwide are opening ComboMATCH on a rolling basis over the next few months
Do you like it?
0 Read more
March 23, 2023
Research dictionary entry
March 23, 2023
Categories
  • Trial Results

Trial Results: ECOG-ACRIN research round-up – Winter 2023

Summaries of recently reported ECOG-ACRIN research results
Do you like it?
0 Read more
January 5, 2023
Crowd of women from behind
January 5, 2023
Categories
  • Trial Results

Trial Results: The TAILORx trial continues to provide reassurance that many women with early breast cancer can safely forego chemotherapy

The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes
Do you like it?
0 Read more
January 5, 2023
Patient and doctor speaking in exam room
January 5, 2023
Categories
  • Trial Results

Trial Results: A recent ECOG-ACRIN study finds excellent results for patients with acute lymphoblastic leukemia (ALL)

Adding immunotherapy to standard chemotherapy keeps most patients in remission and improves their survival
Do you like it?
0 Read more
1234
Next page

News, editorials, and perspectives for the cancer research advocacy community

✕

Categories

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results

Resources

  • Active ECOG-ACRIN Trials
  • Advocacy Organizations
  • Myths and Facts
STAY UP TO DATE

Subscribe to receive updates from the ECOG-ACRIN advocacy committee.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2026 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc